CN115397975A - 改进的t细胞制备方法 - Google Patents

改进的t细胞制备方法 Download PDF

Info

Publication number
CN115397975A
CN115397975A CN202180029152.2A CN202180029152A CN115397975A CN 115397975 A CN115397975 A CN 115397975A CN 202180029152 A CN202180029152 A CN 202180029152A CN 115397975 A CN115397975 A CN 115397975A
Authority
CN
China
Prior art keywords
cells
cell
seq
population
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029152.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·马尔迪洛维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptimmune Ltd
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of CN115397975A publication Critical patent/CN115397975A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180029152.2A 2020-04-17 2021-04-16 改进的t细胞制备方法 Pending CN115397975A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005617.2 2020-04-17
GBGB2005617.2A GB202005617D0 (en) 2020-04-17 2020-04-17 Improved t cell manufacturing process
PCT/GB2021/050909 WO2021209759A1 (en) 2020-04-17 2021-04-16 Improved t cell manufacturing process

Publications (1)

Publication Number Publication Date
CN115397975A true CN115397975A (zh) 2022-11-25

Family

ID=70859978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029152.2A Pending CN115397975A (zh) 2020-04-17 2021-04-16 改进的t细胞制备方法

Country Status (7)

Country Link
US (1) US20230133064A1 (https=)
EP (1) EP4136216A1 (https=)
JP (1) JP7760524B2 (https=)
CN (1) CN115397975A (https=)
CA (1) CA3175266A1 (https=)
GB (1) GB202005617D0 (https=)
WO (1) WO2021209759A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN116496283B (zh) * 2022-01-18 2024-04-19 中国药科大学 五氮杂苊类化合物、制备方法、药物组合物和应用
JP2025515473A (ja) * 2022-04-28 2025-05-15 キュー バイオファーマ， インコーポレイテッド 改変された細胞傷害性ｔ細胞およびその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017070395A1 (en) * 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
US20180320133A1 (en) * 2015-11-05 2018-11-08 City Of Hope Methods for preparing cells for adoptive t cell therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017070395A1 (en) * 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
US20170136063A1 (en) * 2015-10-20 2017-05-18 Kite Pharma, Inc. Methods of Preparing T Cells for T Cell Therapy

Also Published As

Publication number Publication date
GB202005617D0 (en) 2020-06-03
US20230133064A1 (en) 2023-05-04
WO2021209759A1 (en) 2021-10-21
EP4136216A1 (en) 2023-02-22
JP2023521875A (ja) 2023-05-25
CA3175266A1 (en) 2021-10-21
JP7760524B2 (ja) 2025-10-27

Similar Documents

Publication Publication Date Title
JP7181917B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
US20230133064A1 (en) T cell manufacturing process
US20240374728A1 (en) T Cell Modification
EP3768330B1 (en) Methods of enhancing persistence of adoptively infused t cells
CN114174495A (zh) 肿瘤浸润淋巴细胞疗法及其用途
WO2022216837A1 (en) Treatment of cancer with nk cells and an egfr targeted antibody
EP4670732A1 (en) METHOD FOR TREATMENT OF TUMORS USING A COMBINATION OF ONCOLYTIC VIRUS VACCINE AND IMMUNE CELLS
JP2024540102A (ja) 細胞を生成する方法
WO2022229884A2 (en) Recombinant antigen presenting cells
AU2009214980B2 (en) Methods of obtaining antigen-specific T cell populations
WO2022111451A1 (zh) Ras突变体表位肽及识别ras突变体的t细胞受体
US20250090581A1 (en) Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
WO2026007901A1 (zh) 共表达细胞因子的FLT3-CAR-γδT细胞及其应用
HK40117446A (en) T cell modification
CN121368631A (zh) 基于小分子的修饰t细胞的方法
WO2025038745A1 (en) Compositions and methods for activating immune cells
WO2026006604A1 (en) Feeder cell replacement
WO2024206155A1 (en) Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
CN115772497A (zh) 一种靶向g12v突变kras的树突状细胞疫苗
HK40100476A (zh) 扩增t细胞群的方法
CN117915932A (zh) 通用受体免疫细胞疗法
CN117715647A (zh) 用nk细胞和cd38靶向抗体治疗癌症
KR20210141599A (ko) Cd28 t 세포의 배양액, 조성물 및 그 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: K. Maldylovic

Inventor after: G. Hamilton

Inventor before: K. Maldylovic